Dublin, May 26, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Fluidigm Patent Portfolio Analysis" report to their offering.

Fluidigm Has Been Highly Innovative Since The Early 2000s

The microfluidics device market is currently growing, with a wide scope of applications across many industries. With an expected compound annual growth rate of 18%, this market is projected to reach $5.8 billion by 2022.

This high growth rate is largely due to advances in biotechnology, including gene sequencing and genomics. FLUIDIGM is considered as a pioneer in these microfluidic technologies. FLUIDIGM was founded in 1999 to market the integrated fluidic circuit based on a pneumatic rubber valve developed in the laboratory of Stephen Quake, then at Caltech. With this technology, FLUIDIGM became the first company to commercialize a digital polymerase chain reaction (PCR) product in 2006. In 2009, FLUIDIGM was described as the world's leading manufacturer of microfluidic devices by the Nanotechnology Business Journal. Today, among the applications in which FLUIDIGM products are put to use are single-cell genomics, gene expression, single nucleotide polymorphism (SNP) genotyping, targeted resequencing, sample quantitation, copy number variation and mass cytometry.

FLUIDIGM started developing its patent portfolio in the early 2000s and the number of new patents filed each year by FLUIDIGM has remained stable since then. Moreover, FLUIDIGM acquired numerous patents from HELICOS BIOSCIENCES, DVS SCIENCES and ARCXIS BIOTECHNOLOGIES. In recent years, FLUIDIGM's total revenue has decreased. This decline in revenue was partly due to lower sales for genomic products. Therefore, in order to find new growth engines, technologies patented by FLUIDIGM have evolved considerably since its inception. This technological diversification exposes FLUIDIGM to new competitors, especially some big patent assignees that may assert their patents and other proprietary rights against FLUIDIGM.

Citation Network And Competitive IP Environment

FLUIDIGM's patent portfolio has been cited by more than 700 patent assignees in more than 2300 patent families. For its part, FLUIDIGM cites 2600 patent families in its portfolio, representing around 900 assignees. Combining the citation network with the analysis of the content of citing/cited patents, FLUIDIGM's IP competitors have been ranked in order to establish a general view of the competitive IP environment. Thus IP competitors developing microfluidic technologies have been identified for various applications such as protein crystallization, next-generation sequencing (NGS) and digital PCR, single cell genomics or mass cytometry.

Identify Blocking Patents

Analyzing citations and citing applicants, FLUIDIGM's patents with a high potential for IP blocking of other patent applicants in the field of microfluidics have been identified. Most of those patents are related to single cell analysis or digital PCR. Several of these patents were acquired by FLUIDIGM from other companies, or co-filed with academics. The IP blocking power of product categories and applications claimed by FLUIDIGM was also analyzed.

Identify Key Patents

Key patents have been identified based on several indicators, including family size, legal status, citation analysis and impact on microfluidic technology. Newly granted patents, recently expired patents and patents expiring in the next few years have also been analyzed. Several patents were granted recently in the USA, Europe and China, in particular in the field of mass cytometry.

This report also includes an Excel database containing all of the analyzed patents. This database allows for multi-criteria searches and includes patent publication number, hyperlinks to the original documents, priority date, title, abstract, patent assignees and legal status for each member of the patent family.

Key Features Of The Report:

- Time evolution of patent publications and countries of patent filings
- Current legal status of patents
- Citation network, IP collaboration and competitive networks
- Inventor identification
- Key patent analysis
- Patents recently expired
- Granted patents near expiration

Objective Of The Report:

- Understand the IP strategy of FLUIDIGM
- Understand the competitive IP Environment of FLUIDIGM
- Classify FLUIDIGM's patents by their technical issue as well as their IP blocking potential for other IP players
- Identify key patents
- Identify recent granted patents, expired patents and granted patents near expiration

Key Topics Covered:

1. Introduction

2. Methodology

3. Fluidigm IP Profile

4. Segmentation By Product

5. Segmentation By Application

6. License Agreements

7. New Granted Patents

8. Granted Patents Recently Lapsed/Expired

9. Granted Patents Expiring Between 2018 & 2019

10. Conclusion

Companies Mentioned

• 3M
• Abbott
• Affymetrix
• BD
• Beckman Coulter
• Biorad
• Caliper
• Caltech
• DOW
• DVS Sciences
• Fluidigm
• GE Healthcare
• GPB Scientific
• Handylab
• Hitachi
• IBM
• Illumina
• Integenx
• Leco
• LGC
• Life Technologies
• Luminex
• Natera
• Opko
• Perkinelmer
• Philips
• Quanterix
• Raindance
• Roche
• Seqll
• Sequenom
• Shimadzu
• Siemens
• Sony
• Thermo Fisher Scientific

For more information about this report visit http://www.researchandmarkets.com/research/mt5b6q/fluidigm_patent

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Patents

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.